<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent studies report SF3B1 mutations in about 20% of persons of European descent with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Mutations are especially common in persons with ring sideroblasts (RS) </plain></SENT>
<SENT sid="2" pm="."><plain>SF3B1 mutation state was determined in 104 Chinese with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RS </plain></SENT>
<SENT sid="3" pm="."><plain>SF3B1 mutations were found in 55 subjects (53%) including 25 of 39 with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> and RS (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), 26 of 45 (58%) of those with refractory cytopenia with multi-lineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and RS (<z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e>), 3 of 6 with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts-1-RS (<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB1</z:e>-RS) and 1 of 14 with <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB2</z:e>-RS </plain></SENT>
<SENT sid="4" pm="."><plain>There were significant correlations between SF3B1 mutation state and platelet levels (P=0.007), mean RBC corpuscular volume (MCV; (P&lt;0.001), proportion of RS (P&lt;0.001) and percent bone marrow erythroblasts (P=0.012) and myeloblasts (P=0.044) </plain></SENT>
<SENT sid="5" pm="."><plain>Multivariate analyses using a Cox proportional hazards regression model including sex, age, SF3B1 mutation state, <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> concentration, absolute neutrophil level, platelet level, MCV, international prognostic scoring system (IPSS) cytogenetics category, WHO morphologic category and treatment showed SF3B1 mutation state to independently predict survival </plain></SENT>
<SENT sid="6" pm="."><plain>These data increase our knowledge of the impact of SF3B1 mutations in persons with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>They indicate a similar favorable impact of SF3B1 mutation on survival in Chinese with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> as reported for persons of European descent </plain></SENT>
</text></document>